Clinical efficacy of bevacizumab in combination with FOLFOX4 regimen in the treatment of advanced colorectal cancer

doi:10.3877/cma.j.issn.1674-0793.2015.03.007

Abstract

Abstract:

Objective

To explore the efficacy and safety of advanced colorectal cancer patients treated by bevacizumab in combination with FOLFOX4 regimen.

Methods

Eighty-seven patients with advanced colorectal cancer were divided into bevacizumab combined with FOLFOX4 regimen group (the study group, 42 cases) and FOLFOX4 regimen only group (the control group, 45 cases) according to the treatment program. The efficacy, side effects and survival time in two groups were observed and compared.

Results

The response rate (RR) of the study and control group was 40.5% and 17.8%, respectively, and the disease control rate (DCR) of the two groups was 71.4% and 44.4%, respectively; both differences were statistically significant (P<0.05). The median disease free survival (DFS) of study group and control group was 8.9 and 5.8 months, respectively; the median overall survival (OS) of the two groups was 15.6 and 10.6 months, respectively; the differences were statistically significant (P<0.05). The side effects in two groups included diarrhea and gastrointestinal reactions, but all were grade Ⅰ-Ⅱ.

Conclusion

The efficacy of bevacizumab combined with FOLFOX4 regimen is reliable in treating patients with advanced colorectal cancer. It can increase the response rate and prolong median overall survival with low side effects.

Key words: Bevacizumab, FOLFOX4, Advanced colorectal cancer

Zhijun Han. Clinical efficacy of bevacizumab in combination with FOLFOX4 regimen in the treatment of advanced colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(03): 206-210.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2015.03.007

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2015/V09/I03/206

Figures/Tables 5

References 13

[1]	Pourhoseingholi MA. Increased burden of colorectal cancer in Asia[J]. World J Gastrointest Oncol, 2012, 4(4): 68-70.
[2]	Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer[J]. N Eng J Med, 2005, 352(5): 476-487.
[3]	Kabbinavar F, Irl C, Zurlo A, et al. Bevacizumab improves the over-all and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk[J]. Oncology, 2008, 75(3-4): 215-223.
[4]	Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 50(23): 2335-2342.
[5]	Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer[J]. Clin Colorectal Cancer, 2004, 4 Suppl 2: S62-68.
[6]	Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer[J]. Br J Cancer, 1998, 78(10): 1379-1384.
[7]	Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer[J]. Nat Med, 2004, 10(2): 145-147.
[8]	Kiss I, Bortlicek Z, Melichar B, et al. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma[J]. Anticancer Res, 2014, 34(2): 949-954.
[9]	Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer(mCRC): analysis of the TREE-study [J]. J Clin Oncol, 2008, 26(21): 3523-3529.
[10]	Galfrascoli E, Piva S, Cinquini M, et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis[J]. Dig Liver Dis, 2011, 43(4): 286-294.
[11]	Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200[J]. J Clin Oncol, 2007, 25(12): 1539-1544.
[12]	Tappenden P, Jones R, Paisley S, et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer[J]. Health Technol Assess, 2007, 11(12): 1-128.
[13]	Bergsland EK. Update on clinical trials targeting vascular endothelial growth factor in cancer[J]. Am J Health Syst Pharm, 2004, 61(21 Suppl 5): S12-20.

特征		试验组(42例)	对照组(45例)	t/χ²值	P值
年龄(岁)		53.23±10.21	55.68±12.87	0.97	0.33
患病时间(年)		0.65±0.07	0.63±0.06	1.43	0.15
分化程度(例)		?	?	-1.73	0.08
?	高	10	9	?	?
?	中	17	21	?	?
?	低	15	15	?	?
性别(例)		?	?	0.07	0.78
?	男	20	26	?	?
?	女	22	19	?	?

特征		试验组(42例)	对照组(45例)	t/χ²值	P值
年龄(岁)		53.23±10.21	55.68±12.87	0.97	0.33
患病时间(年)		0.65±0.07	0.63±0.06	1.43	0.15
分化程度(例)		?	?	-1.73	0.08
?	高	10	9	?	?
?	中	17	21	?	?
?	低	15	15	?	?
性别(例)		?	?	0.07	0.78
?	男	20	26	?	?
?	女	22	19	?	?

近期疗效	试验组(42例)		对照组(45例)		χ²/z值	P值
近期疗效	例数	%	例数	%	χ²/z值	P值
CR	2	4.76	0	0.00	?	?
PR	15	35.71	8	17.78	?	?
SD	13	30.95	12	26.67	?	?
PD	12	28.57	25	55.56	5.47	0.02
RR	17	40.48	8	17.78	6.47	0.01
DCR	30	71.43	20	44.44	?	?

近期疗效	试验组(42例)		对照组(45例)		χ²/z值	P值
近期疗效	例数	%	例数	%	χ²/z值	P值
CR	2	4.76	0	0.00	?	?
PR	15	35.71	8	17.78	?	?
SD	13	30.95	12	26.67	?	?
PD	12	28.57	25	55.56	5.47	0.02
RR	17	40.48	8	17.78	6.47	0.01
DCR	30	71.43	20	44.44	?	?

项目	Ⅰ级		Ⅱ级
项目	试验组(42例)	对照组(45例)	试验组(42例)	对照组(45例)
腹泻	3(7.14)	1(2.22)	2(4.76)	0(0)
恶心呕吐	2(4.76)	0(0)	1(2.38)	1(2.22)
出血	1(2.38)	2(4.44)	0(0)	0(0)
高血压	0(0)	1(2.22)	1(2.38)	3(6.67)
蛋白尿	0(0)	2(4.44)	0(0)	1(2.22)
心脏毒性	1(2.38)	1(2.22)	0(0)	1(2.22)
总发生率	7(16.67)	7(15.56)	4(9.52)	6(13.33)
χ²值	0.028		0.309
P值	0.868		0.577

Please choose a citation manager

Content to export